C-MYC/BCL6 double-hit high-grade B-cell lymphoma

Clinical trials for C-MYC/BCL6 double-hit high-grade B-cell lymphoma explained in plain language.

Never miss a new study

Get alerted when new C-MYC/BCL6 double-hit high-grade B-cell lymphoma trials appear

Sign up with your email to follow new studies for C-MYC/BCL6 double-hit high-grade B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New combo aims to boost CAR T-Cell success in tough lymphomas

Disease control Ongoing

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

Matched conditions: C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA

Phase 2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

C-MYC/BCL6 double-hit high-grade B-cell lymphoma

Get alerted when new C-MYC/BCL6 double-hit high-grade B-cell lymphoma trials appear

New combo aims to boost CAR T-Cell success in tough lymphomas